Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway
Abstract Even with recent advances in therapy regimen, multiple myeloma patients commonly develop drug resistance and relapse. The relevance of targeting the PD-1/PD-L1 axis has been demonstrated in pre-clinical models. Monotherapy with PD-1 inhibitors produced disappointing results, but combination...
Main Authors: | Rosemarie Tremblay-LeMay, Nasrin Rastgoo, Hong Chang |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-03-01
|
Series: | Journal of Hematology & Oncology |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13045-018-0589-1 |
Similar Items
-
Research Progress of PD-1/PD-L1/2 Pathway in Multiple Myeloma
by: MA Yinjuan, et al.
Published: (2021-06-01) -
The Latest Findings of PD-1/PD-L1 Inhibitor Application in Gynecologic Cancers
by: Omid Kooshkaki, et al.
Published: (2020-07-01) -
PD-L1–PD-1 Pathway in the Pathophysiology of Multiple Myeloma
by: Hideto Tamura, et al.
Published: (2020-04-01) -
Overview of the Cardiotoxicity Induced by PD-1/PD-L1 Immune Checkpoint Inhibitor in Critical Care
by: Ruiting Li, et al.
Published: (2021-06-01) -
PD-1/PD-L1 immune checkpoint inhibitors in glioblastoma: clinical studies, challenges and potential
by: Tianrui Yang, et al.
Published: (2021-02-01)